There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV – Research Report) and Helius Medical Technologies (HSDT – Research Report) with bullish sentiments. AbbVie (ABBV) In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on AbbVie, with a price target of $134.00. The company's shares closed last Friday at $118.85, close to its 52-week high of $121.53. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-70?utm_source=advfn.com&utm_medium=referral
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Helius Medical Technolog... Charts.
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Helius Medical Technolog... Charts.